BTK and neoplasm: In fact, preclinical data indicate that depending on the tumor type, BTK inhibitors used alone can induce cytotoxicity in gliomas[52], be more effective than standard-of-care (SOC) chemotherapy in drug-resistant ovarian cancer[53] or can kill drug-resistant tumor cells when used in combination with SOC chemotherapy or targeted therapy in non-small-cell lung cancer[54], and melanomas (unpublished data).